Werbson Lima Guaraná

Dr. Werbson Lima Guaraná

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2022 in Genes
Verified
Journal Article
Open access
PDF file
WGWerbson Lima Guaraná
Werbson Lima Guaraná
CLCamilla Albertina Dantas de Lima
Camilla Albertina Dantas de Lima
ABAlexandre Domingues Barbosa
Alexandre Domingues Barbosa
Sergio CrovellaSergio Crovella
Sergio Crovella
PSPAULA SANDRIN-GARCIA
PAULA SANDRIN-GARCIA
The immune system plays a critical role in bone homeostasis and, consequently, in the pathophysiology of postmenopausal osteoporosis (OP) since estrogen deficiency induces the inflammasome and increases production of pro-inflammatory cytokines, such as IL-1β and IL-18. NLRP3 inflammasome complex genes have been related with bone homeostasis in cellular and animal models. Here, we performed an association study evaluating SNVs (single-nucleotide variants) in inflammasome NLRP3 pathway genes (NLRP3, CARD8, CASP1, IL-18, and IL-1β) to assess whether variants in these genes could be related to susceptibility to primary OP in postmenopausal women. Methods: We genotyped 196 postmenopausal OP patients and 103 healthy controls using SNV-specific Taqman® probes. Data and statistical analyses were performed using the SNPstats and GraphPad Prism 8 software. Results: We showed an association between NLRP3 rs35829419 CA genotype and lower bone mineral density (BMD) mean at the lumbar spine (p = 0.001); we also observed an association between IL-1β rs16944 AA genotype and higher BMD mean at the total hip (p = 0.009). The IL-1β rs16944 GG was associated with lower alkaline phosphatase levels (ALP) (p = 0.009), and the IL-18 rs1946519 AA was associated with lower vitamin D levels (p = 0.018). Additionally, OP patients presented deficient vitamin D and parathyroid hormone (PTH). Conclusions: The NLRP3 inflammasome complex SNVs were associated with OP severity, possibly indicating these genes’ participation in bone metabolism and its dysregulation.

Verified
Journal Article
Open access
PDF file
WGWerbson Lima Guaraná
Werbson Lima Guaraná
CLCamilla Albertina Dantas de Lima
Camilla Albertina Dantas de Lima
ABAlexandre Domingues Barbosa
Alexandre Domingues Barbosa
Sergio CrovellaSergio Crovella
Sergio Crovella
PSPAULA SANDRIN-GARCIA
PAULA SANDRIN-GARCIA
Aminobisphosphonates (NBPs) are the first-choice medication for osteoporosis (OP); NBP treatment aims at increasing bone mineral density (BMD) by inhibiting the activity of farnesyl diphosphate synthase (FDPS) enzyme in osteoclasts. Despite its efficacy, inadequate response to the drug and side effects have been reported. The A allele of the rs2297480 (A > C) SNP, found in the regulatory region of the FDPS gene, is associated with reduced gene transcription. This study evaluates the FDPS variant rs2297480 (A > C) association with OP patients’ response to alendronate sodium treatment. A total of 304 OP patients and 112 controls were enrolled; patients treated with alendronate sodium for two years were classified, according to BMD variations at specific regions (lumbar spine (L1-L4), femoral neck (FN) and total hip (TH), as responders (OP-R) (n = 20) and non-responders (OP-NR) (n = 40). We observed an association of CC genotype with treatment failure (p = 0.045), followed by a BMD decrease in the regions L1-L4 (CC = −2.21% ± 2.56; p = 0.026) and TH (CC = −2.06% ± 1.84; p = 0.015) after two years of alendronate sodium treatment. Relative expression of the FDPS gene was also evaluated in OP-R and OP-NR patients. Higher expression of the FDPS gene was also observed in OP-NR group (FC = 1.84 ± 0.77; p = 0.006) when compared to OP-R. In conclusion, the influence observed of FDPS expression and the rs2897480 variant on alendronate treatment highlights the importance of a genetic approach to improve the efficacy of treatment for primary osteoporosis.

Verified
Journal Article
Open access
PDF file
COCamila Barbosa Lyra Oliveira
Camila Barbosa Lyra Oliveira
WGWerbson Lima Guaraná
Werbson Lima Guaraná
GVGisele Vajgel
Gisele Vajgel
BJBraziliano Miguel da Silva Júnior
Braziliano Miguel da Silva Júnior
CLCamilla Albertina Dantas de Lima
Camilla Albertina Dantas de Lima
PSPAULA SANDRIN-GARCIA
PAULA SANDRIN-GARCIA
Lupus nephritis (LN) can affect up to 60% of patients with systemic lupus erythematosus (SLE). The NLRP3 inflammasome has been implicated in the pathogenesis of LN. This study aimed to evaluate the role of the NLRP3 inflammasome as a predictor of response to immunosuppressive treatment in patients with active LN. A prospective cohort study was conducted with 20 adult patients with active LN, classes III, IV, and V, from January 2021 to September 2023. Patients were followed up at biopsy (T0) and 6 months (T6) and 12 months (T12) after treatment and classified according to the primary efficacy renal response (PERR) at 12 months. Gene expression of NLRP3, CARD8, CASP1, IL1B, and IL18 was evaluated by RT-qPCR in PBMCs. Immunohistochemistry (IHC) for NLRP3 was performed on kidney tissue. The concentration of cytokine IL-1β was measured using the BD™ Cytometric Bead Array (CBA). The mean age was 31.9 ± 8.3 years, with 19 females and 1 male. After 12 months, 65% of patients achieved PERR. The IHC intensity in inflammatory cells was higher in patients with no PERR (p = 0.0426). In the no-PERR group, the gene expression of IL1B showed a significant increase at T6 (FC = 2.22: p = 0.0037) and T12 (FC = 2.91; p = 0.0001) compared with T0. Relative expression of IL1B was higher in no-PERR patients at T12 compared to the PERR group (p = 0.0477). The no-PERR group also had higher serum IL-1β levels compared to the PERR group at 12 months (2.9 ± 0.5 vs. 2.5 ± 0.7, p = 0.0164). In conclusion, our study evidenced an increase in IL1B expression and IL-1β levels over the 12 months of treatment in no-PERR patients, suggesting a potential biomarker of disease activity. Furthermore, a strong NLRP3 IHC staining score was associated with a higher likelihood of no PERR, highlighting the potential of the NLRP3 inflammasome as a predictor of worse clinical outcomes.

1 February 2023 in International Journal of Immunogenetics
Verified
Journal Article
Closed access
JSJaqueline de Azevêdo Silva
Jaqueline de Azevêdo Silva
CLCamilla Albertina Dantas de Lima
Camilla Albertina Dantas de Lima
WGWerbson Lima Guaraná
Werbson Lima Guaraná
ABAlexandre Domingues Barbosa
Alexandre Domingues Barbosa
TFThiago Sotero Fragoso
Thiago Sotero Fragoso
PSPAULA SANDRIN-GARCIA
PAULA SANDRIN-GARCIA

Verified
Journal Article
Open access
PDF file
CLCamilla Albertina Dantas de Lima
Camilla Albertina Dantas de Lima
ASAnna Paula Oliveira Souza
Anna Paula Oliveira Souza
MSMaria Barreto Seabra
Maria Barreto Seabra
WGWerbson Lima Guaraná
Werbson Lima Guaraná
BOBianca Oliveira
Bianca Oliveira
PSPAULA SANDRIN-GARCIA
PAULA SANDRIN-GARCIA
Osteoporosis (OP) is a complex disease in which several immune-related genes have been identified as contributing to susceptibility and disease progression. Despite efforts to achieve functional validation, many of these genes, such as interferon-gamma (IFNG), remain the subject of unresolved mechanisms. The present study aimed to examine whether the IFNG -1616 (G>A, rs2069705) polymorphism was associated with postmenopausal OP. A total of 251 OP patients and 115 healthy controls were genotyped to assess the association between the IFNG -1616 (G>A, rs2069705) polymorphism and osteoporosis. To further investigate the biological role of IFN-γ in bone metabolism, human SaOs-2 osteosarcoma cells were treated with recombinant IFN-γ (2 and 100 U/mL), and calcification and cell viability were evaluated using Alizarin Red staining and the MTT assay, respectively. We found that the IFNG rs2069705 G allele was associated with an increased risk of OP (OR = 1.45, 95% CI = 1.03–2.05, p = 0.03). Furthermore, serum IFN-γ levels did not differ significantly between genotype groups. In SaOs-2 cells, IFN-γ (2 U/mL) significantly increased viability (p = 0.017) and enhanced calcification in a dose-dependent manner. The IFNG rs2069705 G allele may confer susceptibility to postmenopausal OP. IFN-γ promotes osteoblast viability and mineralization at low concentrations, suggesting a potential anabolic role that warrants further investigation in human primary osteoblasts.